A global action agenda for turning the tide on fatty liver disease
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Background and Aims: Fatty liver disease is a major public health threat due to its very high prevalence and related morbidity and mortality. Focused and dedicated interventions are urgently needed to target disease prevention, treatment, and care. Approach and Results: We developed an aligned, prioritized action agenda for the global fatty liver disease community of practice. Following a Delphi methodology over 2 rounds, a large panel (R1 n = 344, R2 n = 288) reviewed the action priorities using Qualtrics XM, indicating agreement using a 4-point Likert-scale and providing written feedback. Priorities were revised between rounds, and in R2, panelists also ranked the priorities within 6 domains: epidemiology, treatment and care, models of care, education and awareness, patient and community perspectives, and leadership and public health policy. The consensus fatty liver disease action agenda encompasses 29 priorities. In R2, the mean percentage of “agree” responses was 82.4%, with all individual priorities having at least a super-majority of agreement (> 66.7% “agree”). The highest-ranked action priorities included collaboration between liver specialists and primary care doctors on early diagnosis, action to address the needs of people living with multiple morbidities, and the incorporation of fatty liver disease into relevant non-communicable disease strategies and guidance. Conclusions: This consensus-driven multidisciplinary fatty liver disease action agenda developed by care providers, clinical researchers, and public health and policy experts provides a path to reduce the prevalence of fatty liver disease and improve health outcomes. To implement this agenda, concerted efforts will be needed at the global, regional, and national levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000520 · Cited by 3,476
Self-citationYounossi, Z. M., Golabi, P., Paik, J. M., Henry, A., Van Dongen, C., & Henry, L. (2023) · Hepatology · doi:10.1097/hep.0000000000000004 · Cited by 3,383 · cited 2×
“NAFLD, hereafter referred to simply as fatty liver disease, is the most widespread liver disease, with an estimated prevalence of 38% of the global adult population [1] and around 13% of children and adolescents.”
BackgroundInfluentialSelf-citationRinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667
Self-citationSocial determinants of health and diabetes: A scientific review
Hill-Briggs, F., Adler, N. E., Berkowitz, S. A., Chin, M. H., Gary-Webb, T. L., Navas-Acien, A., Thornton, P. L., & Haire-Joshu, D. (2021) · Diabetes Care · doi:10.2337/dci20-0053 · Cited by 1,732 · cited 1×
“[41] In light of this recognition, the panelists agreed that not only social but also commercial determinants of health should be prioritized when developing treatment and care strategies (priority 3.1).”
BackgroundInfluentialTreatment of NAFLD with diet, physical activity and exercise
Romero-Gómez, M., Zelber-Sagi, S., & Trenell, M. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.05.016 · Cited by 1,347
Self-citationThe need for a complex systems model of evidence for public health
Rutter, H., Savona, N., Glonti, K., Bibby, J., Cummins, S., Finegood, D. T., Greaves, F., Harper, L., Hawe, P., Moore, L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31267-9 · Cited by 1,260 · cited 1×
“Public health and health systems increasingly face the complex challenges presented by growing multi-morbidity across NCDs, [49] and fatty liver disease is no exception.”
BackgroundA multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2024) · Annals of Hepatology · doi:10.1016/j.aohep.2023.101133 · Cited by 844
Self-citationDefining and conceptualising the commercial determinants of health
Gilmore, A. B., Fabbri, A., Baum, F., Bertscher, A., Bondy, K., Chang, H.-J., Demaio, S., Erzse, A., Freudenberg, N., Friel, S., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00013-2 · Cited by 758
Advancing the global public health agenda for NAFLD: a consensus statement
Lazarus, J. V., Mark, H. E., Anstee, Q. M., Arab, J. P., Batterham, R. L., Castera, L., Cortez-Pinto, H., Crespo, J., Cusi, K., Dirac, M. A., et al. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00523-4 · Cited by 757 · cited 7×
“[13] Fatty liver disease represents a contemporary public health challenge that requires multidisciplinary and multi-sectoral responses and novel collaboration, from re-orienting health systems to addressing food systems, the built environment, and social deprivation.”
BackgroundMethodInfluentialSelf-citationKarlsen, T. H., Sheron, N., Zelber-Sagi, S., Carrieri, P., Dusheiko, G., Bugianesi, E., Pryke, R., Hutchinson, S. J., Sangro, B., Martin, N. K., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)01701-3 · Cited by 652
Self-citation
Cited by
Israelsen, M., Francque, S., Tsochatzis, E. A., & Krag, A. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01811-7 · Cited by 348
Self-citationMetabolic dysfunction-associated steatotic liver disease in adults
Huang, D. Q., Wong, V. W. S., Rinella, M. E., Boursier, J., Lazarus, J. V., Yki-Järvinen, H., & Loomba, R. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00599-1 · Cited by 293
Self-citationOpportunities and challenges following approval of resmetirom for MASH liver disease
Lazarus, J. V., Ivancovsky Wajcman, D., Mark, H. E., Younossi, Z. M., Kopka, C. J., Cohen, N., Bansal, M. B., Betel, M., & Brennan, P. N. (2024) · Nature Medicine · doi:10.1038/s41591-024-02958-z · Cited by 60
Self-citationIvancovsky Wajcman, D., Byrne, C. J., Dillon, J. F., Brennan, P. N., Villota-Rivas, M., Younossi, Z. M., Allen, A. M., Crespo, J., Gerber, L. H., & Lazarus, J. V. (2026) · Hepatology · doi:10.1097/hep.0000000000001058 · Cited by 33
Self-citationLiu, H., Yin, G., Kohlhepp, M. S., Schumacher, F., Hundertmark, J., Hassan, M. I. A., Heymann, F., Puengel, T., Kleuser, B., Mosig, A. S., et al. (2024) · Advanced Science · doi:10.1002/advs.202403516 · Cited by 30
Metadata
- Authors
- Lazarus, J. V., Mark, H. E., Allen, A. M., Arab, J. P., Carrieri, P., Noureddin, M., Alazawi, W., Alkhouri, N., Alqahtani, S. A., Anstee, Q. M., Arrese, M., Bataller, R., Berg, T., Brennan, P. N., Burra, P., Castro-Narro, G. E., Cortez-Pinto, H., Cusi, K., Dedes, N., Duseja, A., Francque, S. M., Gastaldelli, A., Hagström, H., Huang, T. T. K., Ivancovsky Wajcman, D., Kautz, A., Kopka, C. J., Krag, A., Newsome, P. N., Rinella, M. E., Romero, D., Sarin, S. K., Silva, M., Spearman, C. W., Terrault, N. A., Tsochatzis, E. A., Valenti, L., Villota-Rivas, M., Zelber-Sagi, S., Schattenberg, J. M., Wong, V. W.-S., Younossi, Z. M., & on behalf of the Healthy Livers, H. L. C.
- Venue
- Hepatology
- Published
- 2023-08-04
- Volume
- 79
- Issue
- 2
- Pages
- 502-523
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W4385563490
- Cited by
- 93
- References
- 14
- FWCI
- 15.55
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A global action agenda for turning the tide on fatty liver disease. https://app.cochat.ai/papers/10.1097/hep.0000000000000545
- The paper
- Lazarus, J. V., Mark, H. E., Allen, A. M., Arab, J. P., Carrieri, P., Noureddin, M., Alazawi, W., Alkhouri, N., Alqahtani, S. A., Anstee, Q. M., Arrese, M., Bataller, R., Berg, T., Brennan, P. N., Burra, P., Castro-Narro, G. E., Cortez-Pinto, H., Cusi, K., Dedes, N., . . . on behalf of the Healthy Livers, H. L. C. (2024). A global action agenda for turning the tide on fatty liver disease. Hepatology. https://doi.org/10.1097/hep.0000000000000545
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.